BROMAC
Live / Registered — Registered (as of 18 Jan 2022)
What this means for you
Registered since 18 Jan 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90191359
- Registration number
- 6617801
- Mark type
- Stylized text
- Filed
- 18 Sept 2020
- Published for opposition
- 02 Nov 2021
- Registered
- 18 Jan 2022
- Attorney of record
- JOE MCKINNEY MUNCY
Goods and services
- Class 005 — Pharmaceuticals: Anti-bacterial pharmaceuticals; anti-cancer drugs; anti-cancer pharmaceutical preparations; anti-fungal preparations; antiviral pharmaceutical preparations; bacteria removers, namely, antimicrobial preparations for inhibiting the growth of bacteria; biofilm removers, namely, antimicrobial preparations for inhibiting the growth of biofilms; biological preparations for the treatment of cancer and pseudomyxoma peritonei; chemical preparations containing enzymes for pharmaceutical purposes, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), pneumonia, fungal infections and haemophilia; chemical preparations for pharmaceutical use, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; compounds being pharmaceutical preparations for treating cancer; pharmaceutical compositions for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of pseudomyxoma peritonei; pharmaceutical preparations for use in combination therapy for the treatment of cancer and pseudomyxoma peritonei; pharmaceutical preparations for treating glue ear, cystic fibrosis, sputum retention, chest infections, respiratory conditions, haemophilia, myocardial infarction, coronary artery disease, stroke, massive pulmonary embolism, acute limb ischemia, stent-related thrombosis or haemarthrosis; preparations of plants, namely, plant extracts for pharmaceutical use
Owner
- Mucpharm Pty Ltd, Malvern VIC, AU
- Mucpharm Pty Ltd, Malvern VIC, AU
- Mucpharm Pty Ltd, Malvern VIC, AU
Prosecution history
- 03 Jan 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 03 Jan 2023 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 03 Jan 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 03 Jan 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 18 Jan 2022 — REGISTERED-PRINCIPAL REGISTER
- 02 Nov 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Nov 2021 — PUBLISHED FOR OPPOSITION
- 13 Oct 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 Sept 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 28 Sept 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Sept 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Sept 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Sept 2021 — ASSIGNED TO LIE
- 20 Sept 2021 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 29 Jul 2021 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED